141.82 -0.64 (-0.45%)
After hours: 5:47PM EST
|Bid||142.22 x 300|
|Ask||142.54 x 100|
|Day's Range||141.78 - 143.14|
|52 Week Range||110.76 - 144.35|
|PE Ratio (TTM)||24.78|
|Earnings Date||Jan 23, 2018|
|Forward Dividend & Yield||3.36 (2.37%)|
|1y Target Est||146.82|
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
The S&P 500 and the Dow were trading flat in early afternoon on Thursday as losses in healthcare stocks such as Johnson & Johnson were offset by gains in shares of technology and consumer discretionary companies. Walt Disney struck a deal to buy Twenty-First Century Fox's assets for $52.4 billion in stock.
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
In July 2017, the US FDA (Food and Drug Administration) approved Johnson & Johnson’s (JNJ) Tremfya (guselkumab) for the treatment of individuals with moderate to severe plaque psoriasis.
Headquartered in New York City, pharmaceutical giant Bristol-Myers Squibb (BMY) offers various cardiovascular, immunoscience, neuroscience, oncology, and virology products.
The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.
Pacer, the exchange traded funds issuer behind a unique suite of trend-following funds, added to its lineup Tuesday with the debut of the Pacer WealthShield ETF (CBOE: PWS). The new ETF tracks the Pacer ...
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance.
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
The latest on developments in financial markets (All times local): 4 p.m. Big-company stocks notched gains on Wall Street, bringing more records for major indexes, but smaller companies lagged behind. ...
Now could be the perfect time to add to your portfolio healthcare stocks that can benefit from aging baby boomers and regulatory approvals.
Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has appointed Gary J. Pruden to its Board of Directors. Mr. Pruden ...
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Dec.13 -- Corrine Png, founder and chief executive officer at Crucial Perspective, discusses her outlook for Asia's airline industry in 2018. She speaks on "Bloomberg Markets: Asia."